Journal article
Acute effects of a single, oral dose of d9-tetrahydrocannabinol (THC) and cannabidiol (CBD) administration in healthy volunteers.
R Martin-Santos, JA Crippa, A Batalla, S Bhattacharyya, Z Atakan, S Borgwardt, P Allen, M Seal, K Langohr, M Farré, AW Zuardi, PK McGuire
Current Pharmaceutical Design | BENTHAM SCIENCE PUBL LTD | Published : 2012
Abstract
Animal and humans studies suggest that the two main constituents of cannabis sativa, delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) have quite different acute effects. However, to date the two compounds have largely been studied separately. To evaluate and compare the acute pharmacological effects of both THC and CBD in the same human volunteers. A randomised, double-blind, cross-over, placebo controlled trial was conducted in 16 healthy male subjects. Oral THC 10 mg or CBD 600 mg or placebo was administered in three consecutive sessions, at one-month interval. Physiological measures and symptom ratings were assessed before, and at 1, 2 and 3 hours post drug administration. The are..
View full abstractGrants
Awarded by Medical Research Council
Funding Acknowledgements
This study was supported by grants from the Psychiatry Research Trust, UK and the Ministerio de Sanidad y Consumo: Plan Nacional sobre Drogas: 2006I101, and PI041731/2011, and the Generalitat de Catalunya: SGR2009/1435, Spain. JAC and AWZ are recipients of a CNPq Productivity fellowship (Brazil). SB has received support from the Medical Research Council, UK (Joint MRC/Priory Clinical research training fellowship; G0501775) and is currently supported by a NIHR Clinician Scientist Award (NIHR CS-11-001).